Research Library
GLP-1 SEMA research
6 articles to explore, with links to 7 original sources.
About GLP-1 SEMA
GLP-1 SEMA is the catalog name for semaglutide, a peptide analogue used in GLP-1 receptor research.
Explore study findings
What three semaglutide trials tell us about kidney outcomes
Semaglutide is a modified peptide that activates the glucagon-like peptide-1, or GLP-1, receptor. It is used in several approved formulations for specific conditions.
2 sources (2026)
What BARI-STEP found after bariatric surgery
Semaglutide is a modified GLP-1 receptor agonist peptide. In the 2026 BARI-STEP trial, researchers tested whether it affected body weight in adults who had lost less weight than the study’s threshold after bariatric surgery.
2 sources (2026)
What two Alzheimer’s trials found about oral semaglutide
Semaglutide is a modified GLP-1 receptor agonist. Researchers investigated whether its oral form could slow progression in people with early symptomatic Alzheimer’s disease. Two phase 3 trials reported in 2026 compared it with placebo.
2 sources (2026)
Check methods and identity
Why an alcohol study measured craving and drinking separately
Semaglutide is a GLP-1 receptor agonist with approved uses for specified metabolic and cardiovascular indications, depending on the product. In a 2026 trial, researchers investigated a different question.
2 sources (2026)
What a noninvasive liver score measured in the SAMARA trial
Semaglutide is a modified peptide that activates the GLP-1 receptor. The SAMARA study, published in 2026, asked whether noninvasive tests could detect a change in adults with suspected at-risk metabolic dysfunction-associated steatohepatitis, or MASH, who were assigned to semaglutide or placebo.
2 sources (2026)
Interpret the evidence
How researchers compared semaglutide tablets and injections across trials
Semaglutide is a modified peptide that activates the GLP-1 receptor. It is available in FDA-approved oral and injectable products with product-specific indications.
2 sources (2026)
